Neuroscientific Biopharmaceuticals Ltd (NSB) — Cash Flow-to-Debt Ratio
Neuroscientific Biopharmaceuticals Ltd (NSB) has a Cash Flow-to-Debt Ratio of -3.22x as of June 2025, meaning its operating cash flow of AU$-480.55K could theoretically repay -3% of its total liabilities (AU$149.22K) in one year. Check cash flow reinvestment rate of Neuroscientific Biopharmaceuticals Ltd to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Neuroscientific Biopharmaceuticals Ltd Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Neuroscientific Biopharmaceuticals Ltd across 10 annual periods. Also explore Neuroscientific Biopharmaceuticals Ltd asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Neuroscientific Biopharmaceuticals Ltd (2016–2025)
Year-by-year debt coverage analysis for Neuroscientific Biopharmaceuticals Ltd. For market capitalisation and broader financial context, see Neuroscientific Biopharmaceuticals Ltd stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (AUD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -6.31x | AU$-941.33K | AU$149.22K | ▼ -1321.5% |
| 2024 | 0.52x | AU$44.25K | AU$85.68K | ▲ +113.4% |
| 2023 | -3.86x | AU$-2.30 Million | AU$597.36K | ▼ -23.2% |
| 2022 | -3.13x | AU$-6.94 Million | AU$2.22 Million | ▲ +73.1% |
| 2021 | -11.64x | AU$-2.60 Million | AU$223.41K | ▲ +54.8% |
| 2020 | -25.77x | AU$-2.28 Million | AU$88.53K | ▼ -14.4% |
| 2019 | -22.53x | AU$-1.41 Million | AU$62.48K | ▼ -245.6% |
| 2018 | -6.52x | AU$-497.91K | AU$76.39K | ▼ -50.9% |
| 2017 | -4.32x | AU$-186.42K | AU$43.15K | ▼ -501.2% |
| 2016 | -0.72x | AU$-87.76K | AU$122.12K | — |